Background: Cough-variant asthma (CVA), a precursor of typical asthma, is the main cause of chronic cough. We hypothesize that yukmijihwang-tang (YJT), which has been used for chronic cough in traditional medicine and has been reported to have an anti-inflammatory effect, could be an adjuvant to asthma treatment. Methods: We plan a randomized, double-blind, placebo-controlled, multicenter, phase 2 trial to investigate the efficacy and safety of YJT in CVA patients. A total of 60 patients with CVA will be recruited and randomly assigned to either a high-dose YJT group, standard-dose YJT group, or control group (placebo) in a 1:1:1 allocation ratio after a 2-week run-in period. For the run-in period, only inhaled corticosteroids (ICSs) will be used, and the investigational drug will be administered once a day with concomitant ICS for 6 weeks. Data will be collected at baseline, week 3, and week 6, and the primary outcome measure will be the mean cough symptom score (CSS) change before and after medication. The secondary outcome measures will include the Leicester cough questionnaire-Korean version (LCQ-K) score, eosinophil count and eosinophil cationic protein level, pulmonary function test, and the number of uses of rescue medication, and so on. Conclusion: This study aimed to evaluate the efficacy and safety of YJT in concomitant treatment with ICS in patients with CVA and to determine the optimal dosage of YJT. The results are expected to provide evidence for the use of YJT as an adjuvant treatment for CVA.

Journal Section:
Research Article / Originalarbeit
Keywords:
Cough-variant asthma, Korean medicine, Herbal medicine, Yukmijihwang-tang
1.
Corrao WM, Braman SS, Irwin RS. Chronic cough as the sole presenting manifestation of bronchial asthma. N Engl J Med. 1979;300(12):633–7.
https://doi.org/10.1056/NEJM197903223001201
2.
Johnson D, Osborn LM. Cough variant asthma: a review of the clinical literature. J Asthma. 1991;28(2):85–90.
https://doi.org/10.3109/02770909109082732
3.
Nakajima T, Nishimura Y, Nishiuma T, Kotani Y, Funada Y, Nakata H, et al. Characteristics of patients with chronic cough who developed classic asthma during the course of cough variant asthma: a longitudinal study. Respiration. 2005;72(6):606–11.
https://doi.org/10.1159/000087459
4.
Matsumoto H, Niimi A, Takemura M, Ueda T, Tabuena R, Yamaguchi M, et al. Prognosis of cough variant asthma: a retrospective analysis. J Asthma. 2006;43(2):131–5.
https://doi.org/10.1080/02770900500498477
5.
Cheriyan S, Greenberger PA, Patterson R. Outcome of cough variant asthma treated with inhaled steroids. Ann Allergy. 1994;73(6):478–80.
6.
Miwa N, Nagano T, Ohnishi H, Nishiuma T, Takenaka K, Shirotani T, et al. An open-label, multi-institutional, randomized study to evaluate the additive effect of a leukotriene receptor antagonist on cough score in patients with cough-variant asthma being treated with inhaled corticosteroids. Kobe J Med Sci. 2018;64(4):E134–9.
7.
Doan T, Patterson R, Greenberger PA. Cough variant asthma: usefulness of a diagnostic-therapeutic trial with prednisone. Ann Allergy. 1992;69(6):505–9.
8.
Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941–55.
https://doi.org/10.1001/archinte.159.9.941
9.
Lee JK, Lee NH, Ha HK, et al. Analysis of studies on Yukmijihwang-tang for establishment of evidence based medicine. J Physiol Pathol Korean Med. 2009;23(1):15–26.
10.
Ju C, Hwang W, Heo T, Jung H, Jung S, Rhee H. The inhibitory effects of yukmijihwang-tang-hap-sabaek-san and root Cortex of morus alba L. On the IL-6, IL-8 and GM-CSF mRNA levels in human epithelial cells. J Intern Korean Med. 2001;22(3):415–22.
11.
Jeon J, Jeong H. Experimental effect of yukmi-jihwang-tang on the T-lymphocytes and macrophages. J Intern Korean Med. 2000;21(2):243–50.
12.
Shioya T, Satake M, Sano M, Kagaya M, Watanabe A, Sato K, et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on cough variant asthma. Eur J Clin Pharmacol. 2002;58(3):171–6.
https://doi.org/10.1007/s00228-002-0468-z
13.
Spector SL, Tan RA. Effectiveness of montelukast in the treatment of cough variant asthma. Ann Allergy Asthma Immunol. 2004;93(3):232–6.
https://doi.org/10.1016/S1081-1206(10)61493-7
14.
Tamaoki J, Yokohori N, Tagaya E, Kirishi S, Miyamoto Y, Ochiai K, et al. Comparable effect of a leukotriene receptor antagonist and long-acting beta-adrenergic agonist in cough variant asthma. Allergy Asthma Proc. 2010;31(5):78–84.
https://doi.org/10.2500/aap.2010.31.3366
15.
Ha H, Lee JK, Lee HY, Seo CS, Lee MY, Huh JI, et al. Evaluation of genotoxicity of Yukmijihwang-tang, a herbal formula. Regul Toxicol Pharmacol. 2011;59(3):391–6.
https://doi.org/10.1016/j.yrtph.2011.01.002
16.
Kwon J, Moon J, Kim S, Song WJ, Kim MH, Kang MG, et al. Korean version of the Cough Symptom Score: clinical utility and validity for chronic cough. Korean J Intern Med. 2017;32(5):910–5.
https://doi.org/10.3904/kjim.2016.132
17.
Han J, Jung I, Kang W, Kim S, Yeo Y, Park Y. Reliability and validity of leicester cough questionnaire Korean version. Chron Respir Dis. 2014;11(3):147–52.
https://doi.org/10.1177/1479972314536206
18.
Gibson PG, Vertigan AE. Management of chronic refractory cough. BMJ. 2015:h5590.
https://doi.org/10.1136/bmj.h5590
19.
Morice AH, Fontana GA, Sovijarvi ARA, Pistolesi M, Chung KF, Widdicombe J, et al. The diagnosis and management of chronic cough. Eur Respir J. 2004;24(3):481–92.
https://doi.org/10.1183/09031936.04.00027804
20.
Chen Y, Shergis JL, Wu Z, Guo XF, Zhang AL, Wu L, et al. Herbal medicine for adult patients with cough variant asthma: a systematic review and meta-analysis. Evid base Compl Alternative Med. 2021;2021:2021–13.
https://doi.org/10.1155/2021/5853137
21.
Fan R, Wen Z, Wang D, Yang RY, Ou AH, Jin LS, et al. Chinese herbal medicine for the treatment of cough variant asthma: a study protocol for a double-blind randomized controlled trial. Trials. 2019;20(1):3–8.
https://doi.org/10.1186/s13063-018-3073-x
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.